CYCLOPHOSPHAMIDE AND HUMAN ORGAN TRANSPLANTATION

T. E. Starzl, I. Penn, G. Schroter, C. W. Putnam, C. G. Halgrimson, G. Martineau, H. Amemiya, C. G. Groth

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Cyclophosphamide, a drug that has not previously had an important role in whole-organ transplantation, was given as a primary immunosuppressant to one liver and eleven kidney recipients, in combination with prednisone and horse antilymphocyte globulin. One of the patients died despite good renal-graft function. Two kidneys from a common cadaveric donor failed. The other nine patients have excellent function of their homografts after 2-3 months. Cyclophosphamide was substituted for azathioprine in one hepatic and five renal recipients who were suspected of having liver toxicity from azathioprine 3 months to almost 8 years post-transplantation. Graft function was maintained after this change, and the evidence of liver injury subsided.

Original languageEnglish (US)
Pages (from-to)70-74
Number of pages5
JournalThe Lancet
Volume298
Issue number7715
DOIs
StatePublished - Jul 10 1971
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'CYCLOPHOSPHAMIDE AND HUMAN ORGAN TRANSPLANTATION'. Together they form a unique fingerprint.

Cite this